Arcadia Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-In · Accumulated · Accumulated Other · Non-Controlling · TotalStockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Comprehensive Income | Interest | Equity | |
| Balance at December 31, 2024 | 1,364,940 | $65 | $285,036 | $(278,878) | $— | $— | $6,223 |
| Issuance of shares related to employee stock purchase plan | 2,100 | — | 5 | — | — | — | 5 |
| Stock-based compensation | — | — | 78 | — | — | — | 78 |
| Net income | — | — | — | 2,599 | — | — | 2,599 |
| Balance at March 31, 2025 | 1,367,040 | $65 | $285,119 | $(276,279) | $— | $— | $8,905 |
| Stock-based compensation | — | — | 86 | — | — | — | 86 |
| Net loss | — | — | — | (4,458) | — | — | (4,458) |
| Balance at June 30, 2025 | 1,367,040 | $65 | $285,205 | $(280,737) | $— | $— | $4,533 |
| Issuance of shares related to employee stock purchase plan | 389 | — | 1 | — | — | — | 1 |
| Stock-based compensation | — | — | 53 | — | — | — | 53 |
| Net income | — | — | — | 856 | — | — | 856 |
| Balance at September 30, 2025 | 1,367,429 | $65 | $285,259 | $(279,881) | $— | $— | $5,443 |
| Common Stock · AdditionalPaid-In · Accumulated · Accumulated Other · Non-Controlling · TotalStockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Comprehensive Income | Interest | Equity | |
| Balance at December 31, 2023 | 1,285,337 | $65 | $284,515 | $(271,840) | $101 | $(138) | $12,703 |
| Issuance of shares related to March 2023 pre-funded warrants exercise | 75,000 | — | — | — | — | — | — |
| Issuance of shares related to employee stock purchase plan | 2,503 | — | 5 | — | — | — | 5 |
| Stock-based compensation | — | — | 138 | — | — | — | 138 |
| Unrealized gains on available-for-sale securities | — | — | — | — | 60 | — | 60 |
| Net loss | — | — | — | (2,423) | — | — | (2,423) |
| Balance at March 31, 2024 | 1,362,840 | $65 | $284,658 | $(274,263) | $161 | $(138) | $10,483 |
| Issuance of shares related to March 2023 pre-funded warrants exercise | — | — | — | — | — | — | — |
| Issuance of shares related to reverse stock split | — | — | — | — | — | — | — |
| Stock-based compensation | — | — | 102 | — | — | — | 102 |
| Change in unrealized gains on available-for-sale securities | — | — | — | — | (80) | — | (80) |
| Net income | — | — | — | 1,061 | — | — | 1,061 |
| Balance at June 30, 2024 | 1,362,840 | $65 | $284,760 | $(273,202) | $81 | $(138) | $11,566 |
| Issuance of shares related to employee stock purchase plan | 2,100 | — | 4 | — | — | — | 4 |
| Stock-based compensation | — | — | 155 | — | — | — | 155 |
| Unrealized gains on available-for-sale securities | — | — | — | — | 36 | — | 36 |
| Net loss | — | — | — | (1,612) | — | — | (1,612) |
| Balance at September 30, 2024 | 1,364,940 | $65 | $284,919 | $(274,814) | $117 | $(138) | $10,149 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.